{"id":3984,"text":"The purpose of this study was to investigate the herb–drug interactions involving red ginseng extract (RGE) or ginsenoside Rc with valsartan, a substrate for organic anion transporting polypeptide (OATP\/Oatp) transporters.","label":[[82,107,"Herb name"],[111,125,"Herb name"],[131,140,"Drug"],[158,221,"Target"]],"Comments":[]}
{"id":3985,"text":"In HEK293 cells overexpressing drug transporters, the protopanaxadiol (PPD)-type ginsenosides- Rb1, Rb2, Rc, Rd, Rg3, compound K, and Rh2-inhibited human OATP1B1 and OATP1B3 transporters (IC Ginseng is one of the most popular plants in Asia, Europe, and USA [1,2] owing to its vitality restoration and immunostimulating effect [1].","label":[[54,93,"Herb name"],[95,98,"Herb name"],[100,103,"Herb name"],[105,107,"Herb name"],[109,111,"Herb name"],[113,116,"Herb name"],[118,128,"Herb name"],[134,137,"Herb name"],[154,161,"Target"],[166,173,"Target"],[188,190,"Parameter"],[191,198,"Herb name"]],"Comments":[]}
{"id":3986,"text":"The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].","label":[[28,35,"Herb name"],[118,139,"Pathology"]],"Comments":[]}
{"id":3987,"text":"Ginseng is also commonly used due to its potential as a chemo-preventive agent and adjuvant therapy [9].","label":[[0,7,"Herb name"]],"Comments":[]}
{"id":3988,"text":"These pharmacological activities have also been observed for various ginsenosides mainly present in ginseng products [4].","label":[[69,81,"Herb name"],[100,107,"Herb name"]],"Comments":[]}
{"id":3989,"text":"Due to the growing use of herbal medicine and convenience of taking herbal formulations, herb–drug interactions caused by the co-administration of herbal medicine with therapeutic drugs have also rapidly increased from 13.8% in 2010 to 17.3% in 2013 among adverse drug reactions in China [10].","label":[[256,278,"Pathology"]],"Comments":[]}
{"id":3990,"text":"The most frequently reported cases of herb–drug interactions include the modulation of drug metabolizing enzymes and transporters by herbal medicines and the causative pharmacokinetic alterations of co-administered therapeutic drugs that may acts as substrates for drug metabolizing enzymes and transporters [8,11].","label":[[20,34,"Study"]],"Comments":[]}
{"id":3991,"text":"In case of ginseng interactions, it was reported that no herb–drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5–2.0 g\/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].","label":[[11,18,"Herb name"],[107,113,"Ethnic group"],[114,139,"Herb name"],[141,153,"Amount"],[189,218,"Target"],[226,252,"Target"]],"Comments":[]}
{"id":3992,"text":"Repeated oral administration of RGE (0.5 g\/kg for 2 weeks in mice and 85 mg total ginsenosides for 2 weeks in human) did not alter the metabolic activity of above 5 CYP enzymes in the mouse liver [13] and could not induce clinically significant interaction in human [14,15].","label":[[32,35,"Herb name"],[37,45,"Amount"],[46,57,"Duration"],[70,75,"Amount"],[82,94,"Herb name"],[95,106,"Duration"],[165,176,"Target"]],"Comments":[]}
{"id":3993,"text":"In a study conducted by Malati et al.","label":[],"Comments":[]}
{"id":3994,"text":"[16], Korean ginseng (0.5 g capsule twice daily for 28 days) induced CYP3A activity and decrease plasma concentration of midazolam following oral administration of 8 mg midazolam.","label":[[6,12,"Ethnic group"],[13,20,"Herb name"],[22,27,"Amount"],[36,47,"Frequency"],[48,59,"Duration"],[69,74,"Target"],[121,130,"Drug"],[164,168,"Amount"],[169,178,"Drug"]],"Comments":[]}
{"id":3995,"text":"The expression levels of organic anion transporter 1 (Oat1) and Oat3 in the kidney and P-glycoprotein (P-gp) in the liver were increased by the repeated administration of RGE (30–300 mg\/kg for 2 weeks) in mice, which were accompanied with the dose dependent decrease in the area under the plasma concentration-time curve (AUC) of fexofenadine, a substrate for P-gp [17].","label":[[25,59,"Target"],[64,68,"Target"],[87,108,"Target"],[171,174,"Herb name"],[176,188,"Amount"],[189,200,"Duration"],[274,326,"Parameter"],[330,342,"Drug"],[360,364,"Target"]],"Comments":[]}
{"id":3996,"text":"In another study using rats, the bioavailability of fexofenadine was decreased by 16.1% following repeated administration of ginseng radix extract (150 mg\/kg\/day for 2 weeks), which may be explained by reduced absorption of fexofenadine due to the induction of intestinal P-gp [18].","label":[[33,48,"Parameter"],[52,64,"Drug"],[125,146,"Herb name"],[148,157,"Amount"],[157,161,"Frequency"],[162,173,"Duration"],[224,236,"Drug"],[272,276,"Target"]],"Comments":[]}
{"id":3997,"text":"Repeated RGE treatment was reported to decrease multidrug resistance-related protein 2 (Mrp2) mRNA and protein expression, consequently decreasing the biliary excretion of methotrexate and increasing plasma concentration [8].","label":[[9,12,"Herb name"],[48,93,"Target"],[94,98,"Target"],[172,184,"Drug"]],"Comments":[]}
{"id":3998,"text":"Intestinal and hepatic organic cation transporter 1 (Oct1) expression was increased and decreased, respectively, in rats following repeated administration of RGE (1.5 g\/kg for 7 days) [19].","label":[[23,58,"Target"],[158,161,"Herb name"],[163,171,"Amount"],[172,182,"Duration"]],"Comments":[]}
{"id":3999,"text":"Although repeated administration of RGE suggested modulation of transporter activity, the systematic pharmacokinetic ginseng-drug interaction on drug transporters and clinical evidence is still limited [20].","label":[[36,39,"Herb name"],[117,124,"Herb name"]],"Comments":[]}
{"id":4000,"text":"In addition to ginseng products, individual ginsenosides can also modulate drug-metabolizing enzymes or transporters.","label":[[15,22,"Herb name"],[44,56,"Herb name"]],"Comments":[]}
{"id":4001,"text":"For example, Rb1, the most abundant ginsenoside in RGE, was found to significantly inhibit CYP2C9 (IC The inhibitory effects of ginsenosides on drug transporters were evaluated using HEK293 cells overexpressing OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3 and HEK293-mock cells.","label":[[13,16,"Herb name"],[36,47,"Herb name"],[51,54,"Herb name"],[91,97,"Target"],[99,101,"Parameter"],[128,140,"Herb name"],[211,215,"Target"],[217,221,"Target"],[223,227,"Target"],[229,233,"Target"],[235,242,"Target"],[244,251,"Target"]],"Comments":[]}
{"id":4002,"text":"First, we measured the uptake of probe substrates into respective transporters in the presence of typical inhibitors of the transporters for the system validation (Figure 1).","label":[],"Comments":[]}
{"id":4003,"text":"Triethylammonium (TEA) inhibited OCT1 and OCT2 with IC We then evaluated the modulation of drug transporters by ginsenosides.","label":[[33,37,"Target"],[42,46,"Target"],[52,54,"Parameter"],[112,124,"Target"]],"Comments":[]}
{"id":4004,"text":"We found that ginsenosides selectively inhibited OATP transport activities but not OCTs and OATs.","label":[[14,26,"Herb name"],[49,53,"Target"],[83,87,"Target"],[92,96,"Target"]],"Comments":[]}
{"id":4005,"text":"Ginsenosides Rb1, Rb2, Rc, Rd, Rg3, compound K, Rh2, PPD, PPT, and Rh1 had IC Based on the significant inhibitory effect of ginsenosides on OATP1B1 and OATP1B3, we further evaluated the in vivo herb–drug interaction using a substrate drug for both OATP1B1 and OATP1B3.","label":[[0,12,"Herb name"],[13,16,"Herb name"],[18,21,"Herb name"],[23,25,"Herb name"],[27,29,"Herb name"],[31,34,"Herb name"],[36,46,"Herb name"],[48,51,"Herb name"],[53,56,"Herb name"],[58,61,"Herb name"],[67,70,"Herb name"],[75,77,"Parameter"],[124,136,"Herb name"],[140,147,"Target"],[152,159,"Target"],[248,255,"Target"],[260,267,"Target"]],"Comments":[]}
{"id":4006,"text":"Valsartan was selected as a substrate for both OATP1B1 and OATP1B3 (Figure 4).","label":[[0,9,"Drug"],[47,54,"Target"],[59,66,"Target"]],"Comments":[]}
{"id":4007,"text":"Valsartan uptake by HEK293 cells expressing OATP1B1 and OATP1B3 was increased by 19.8-fold and 26.1-fold, respectively, compared with the uptake by HEK293-mock cells.","label":[[0,9,"Drug"],[44,51,"Target"],[56,63,"Target"]],"Comments":[]}
{"id":4008,"text":"OATP1B1- and OATP1B3-mediated valsartan uptake was inhibited by rifampin in a concentration-dependent manner, and the inhibition profile showed IC In addition to this, valsartan has been reported to be mainly eliminated via biliary excretion mediated by OATP1B1 and OATP1B3 in human and Oatps in rats.","label":[[0,7,"Target"],[13,20,"Target"],[30,39,"Drug"],[64,72,"Drug"],[144,146,"Parameter"],[168,177,"Drug"],[254,262,"Target"],[266,273,"Target"],[287,292,"Target"]],"Comments":[]}
{"id":4009,"text":"The contribution of Oatp transporters in the hepato-biliary excretion was about 70–85% in both rats and human [29,30].","label":[[20,37,"Target"]],"Comments":[]}
{"id":4010,"text":"The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb–drug interaction between valsartan and RGE or ginsenosides.","label":[[25,34,"Drug"],[83,87,"Target"],[102,106,"Target"],[156,165,"Drug"],[170,173,"Herb name"],[177,189,"Herb name"]],"Comments":[]}
{"id":4011,"text":"We initially investigated the effect of rifampin on the valsartan pharmacokinetics following the intravenous injection of valsartan at a dose of 1 mg\/kg as a positive control group and the results were shown in Figure 5A and Table 2.","label":[[40,48,"Drug"],[56,65,"Drug"],[122,131,"Drug"],[145,152,"Amount"]],"Comments":[]}
{"id":4012,"text":"The plasma concentration of valsartan was increased by co-treatment with rifampin, a typical inhibitor of OATP or Oatp transporters.","label":[[28,37,"Drug"],[73,81,"Drug"],[106,110,"Target"],[114,131,"Target"]],"Comments":[]}
{"id":4013,"text":"Thus, pharmacokinetic parameters such as the area under the plasma concentration-time curve (AUC To explain the lack of herb–drug interaction between RGE and valsartan, we measured the plasma concentrations of ginsenosides following repeated administration of RGE using the previously developed analytical method by LC-MS\/MS [19,31].","label":[[41,91,"Parameter"],[93,96,"Parameter"],[150,153,"Herb name"],[158,167,"Drug"],[210,222,"Herb name"],[260,263,"Herb name"]],"Comments":[]}
{"id":4014,"text":"Among the 14 ginsenosides examined (Rb1, Rb2, Rc, Rd, Rh2, Rg3, F2, compound K, PPD, Re, Rh1, Rg1, F1, and PPT), 6 ginsenosides were detected in the plasma samples and the plasma concentrations of the 6 ginsenosides are shown in Figure 6.","label":[[13,25,"Herb name"],[36,39,"Herb name"],[41,44,"Herb name"],[46,48,"Herb name"],[50,52,"Herb name"],[54,57,"Herb name"],[59,62,"Herb name"],[64,66,"Herb name"],[68,78,"Herb name"],[80,83,"Herb name"],[85,87,"Herb name"],[89,92,"Herb name"],[94,97,"Herb name"],[99,101,"Herb name"],[107,110,"Herb name"],[115,127,"Herb name"],[203,215,"Herb name"]],"Comments":[]}
{"id":4015,"text":"The plasma concentrations of the ginsenosides Rb1, Rb2, Rc, and Rd in rats after multiple administration of RGE (1.5 g\/kg\/day) for 1 week were consistent with previous results [8,19].","label":[[33,45,"Herb name"],[46,49,"Herb name"],[51,54,"Herb name"],[56,58,"Herb name"],[64,66,"Herb name"],[108,111,"Herb name"],[113,121,"Amount"],[121,125,"Frequency"],[127,137,"Duration"]],"Comments":[]}
{"id":4016,"text":"The ginsenosides Rh2, Rg3, F2, and compound K (intermediate metabolites of PPD-type ginsenosides [32], were not detected.","label":[[4,16,"Herb name"],[17,20,"Herb name"],[22,25,"Herb name"],[27,29,"Herb name"],[35,45,"Herb name"],[75,96,"Herb name"]],"Comments":[]}
{"id":4017,"text":"PPD, a final metabolite of PPD-type ginsenosides, was detected in the rat plasma and showed a slow elimination process (Figure 6E and Table 3).","label":[[0,3,"Herb name"],[27,48,"Herb name"]],"Comments":[]}
{"id":4018,"text":"Similarly, Re, Rh1, Rg1, and F1 (PPT-type ginsenosides and their intermediate metabolites [32]) were not detected in the rat plasma.","label":[[11,13,"Herb name"],[15,18,"Herb name"],[20,23,"Herb name"],[29,31,"Herb name"],[33,54,"Herb name"]],"Comments":[]}
{"id":4019,"text":"PPT, a final metabolite of PPT-type ginsenosides, was detected and also showed a slow elimination process (Figure 6F and Table 3).","label":[[0,3,"Herb name"],[27,48,"Herb name"]],"Comments":[]}
{"id":4020,"text":"As shown in Table 3. the maximum plasma concentrations of Rb1, Rb2, Rc, Rd, PPD, and PPT were 17.84 ± 2.34 ng\/mL (15.8 nM), 10.02 ± 1.04 ng\/mL (9.1 nM), 11.67 ± 2.49 (10.6 nM), 5.10 ± 0.74 ng\/mL (5.3 nM), 20.56 ± 9.47 ng\/mL (48.4 nM), and 16.97 ± 8.99 ng\/mL (38.5 nM), respectively.","label":[[25,54,"Parameter"],[58,61,"Herb name"],[63,66,"Herb name"],[68,70,"Herb name"],[72,74,"Herb name"],[76,79,"Herb name"],[85,88,"Herb name"],[94,112,"Amount"],[114,121,"Amount"],[124,142,"Amount"],[144,150,"Amount"],[153,165,"Amount"],[167,174,"Amount"],[177,194,"Amount"],[196,202,"Amount"],[205,223,"Amount"],[225,232,"Amount"],[239,257,"Amount"],[259,266,"Amount"]],"Comments":[]}
{"id":4021,"text":"These concentrations might be far below the IC We further investigated herb–drug interaction between valsartan and individual ginsenoside.","label":[[44,46,"Parameter"],[101,110,"Drug"],[126,137,"Herb name"]],"Comments":[]}
{"id":4022,"text":"At first, the inhibitory effect of ginsenoside Rb1, Rb2, and Rc on the OATP1B1 and OATP1B3-mediated valsartan uptake was measured.","label":[[35,46,"Herb name"],[47,50,"Herb name"],[52,55,"Herb name"],[61,63,"Herb name"],[71,78,"Target"],[83,90,"Target"],[100,109,"Drug"]],"Comments":[]}
{"id":4023,"text":"Ginsenoside Rb1, Rb2, and Rc was selected considering its stability and high plasma concentation in rat plasma (based on Figure 6) and in human plasma [31,33] as well as its low IC Next, we investigated whether the high plasma concentration of individual ginsenoside (Rc) above the IC To investigate the cause of the minimal herb–drug interaction between Rc and valsartan, we measured the plasma and liver distribution of Rc following intravenous injection of Rc.","label":[[0,11,"Herb name"],[12,15,"Herb name"],[17,20,"Herb name"],[26,28,"Herb name"],[178,180,"Parameter"],[255,271,"Herb name"],[282,284,"Parameter"],[355,357,"Herb name"],[362,371,"Drug"],[422,424,"Herb name"],[460,462,"Herb name"]],"Comments":[]}
{"id":4024,"text":"As shown in Figure 9A, Rc was not widely distributed to the liver; thus, the liver concentration of Rc was lower than the plasma concentration of Rc and the liver-to-plasma concentration ratio of Rc was in the range of 0.13–0.2.","label":[[23,25,"Herb name"],[100,102,"Herb name"],[146,148,"Herb name"],[196,198,"Herb name"]],"Comments":[]}
{"id":4025,"text":"In addition, these tri-glycosylated ginsenosides showed high protein binding in rat plasma and liver homogenates (Figure 9B).","label":[[19,48,"Herb name"]],"Comments":[]}
{"id":4026,"text":"When calculated free Rc concentration in our system, free Rc concentration was estimated to be 0.08–0.34 μM in the rat plasma and 0.07–0.14 μM in the rat liver.","label":[[21,23,"Herb name"],[58,60,"Herb name"],[95,107,"Amount"],[130,142,"Amount"]],"Comments":[]}
{"id":4027,"text":"As Oatp transporters are located in the sinusoidal membrane of hepatocytes, the low hepatic distribution and high protein binding of Rc may contribute to the negative inhibitory effect of Rc on Oatp transporters in vivo, which might result in the negligible pharmacokinetic interaction between Rc and valsartan.","label":[[3,20,"Target"],[133,135,"Herb name"],[188,190,"Herb name"],[194,211,"Target"],[294,296,"Herb name"],[301,310,"Drug"]],"Comments":[]}
{"id":4028,"text":"Similarly, limited herb–drug interaction between valsartan and ginsenoside Rb1 and Rb2 would be expected based on their similarity in the structure, protein binding features, and inhibitory effect on OATP transporters (Figure 7 and Figure 9B, Table 1).","label":[[49,58,"Drug"],[63,74,"Herb name"],[75,78,"Herb name"],[83,86,"Herb name"],[200,204,"Target"]],"Comments":[]}
{"id":4029,"text":"In the present study, the inhibitory effect of 12 ginsenosides (Rb1, Rb2, Rc, Rd, compound K, Rg3, Rh2, PPD, PPT, Re, Rg1, and Rh1) on HEK293 cells overexpressing drug transporters such as OCT1, OCT2, OAT1, OAT3, OATP1B1, and OATP1B3 was evaluated.","label":[[50,62,"Herb name"],[64,67,"Herb name"],[69,72,"Herb name"],[74,76,"Herb name"],[78,80,"Herb name"],[82,92,"Herb name"],[94,97,"Herb name"],[99,102,"Herb name"],[104,107,"Herb name"],[109,112,"Herb name"],[114,116,"Herb name"],[118,121,"Herb name"],[127,130,"Herb name"],[189,193,"Target"],[195,199,"Target"],[201,205,"Target"],[207,211,"Target"],[213,220,"Target"],[226,233,"Target"]],"Comments":[]}
{"id":4030,"text":"The transport activity of OCT1, OCT2, OAT1, and OAT3 was not modulated by the 12 ginsenosides.","label":[[26,30,"Target"],[32,36,"Target"],[38,42,"Target"],[48,52,"Target"],[81,93,"Herb name"]],"Comments":[]}
{"id":4031,"text":"However, Rb1, Rb2, Rc, Rd, Rg3, compound K, and Rh2 (PPD-type ginsenosides) inhibited OATP1B1 with IC This possible herb–drug interaction led us to investigate OATP-mediated in vivo pharmacokinetic herb–drug interactions because OATPs play important roles in the intestinal absorption and hepatic uptake of various therapeutic reagents.","label":[[9,12,"Herb name"],[14,17,"Herb name"],[19,21,"Herb name"],[23,25,"Herb name"],[27,30,"Herb name"],[32,42,"Herb name"],[48,51,"Herb name"],[53,74,"Herb name"],[86,93,"Target"],[99,101,"Parameter"],[160,164,"Target"],[229,234,"Target"]],"Comments":[]}
{"id":4032,"text":"And a lot of clinically relevant herb–drug interactions and drug-drug interactions have been reported to be caused by the inhibition of OATPs [34].","label":[[136,141,"Target"]],"Comments":[]}
{"id":4033,"text":"For example, gemfibrozil and cyclosporine can increase the plasma exposure of pravastatin, pitavastatin, and atorvastatin through the inhibition of hepatic OATPs [34].","label":[[13,24,"Drug"],[29,41,"Drug"],[78,89,"Drug"],[91,103,"Drug"],[109,121,"Drug"],[148,161,"Target"]],"Comments":[]}
{"id":4034,"text":"Quercetin (1500 mg\/day for 7 days) and grapefruit juice (300 mL of pure juice) can inhibit intestinal OATP, thereby decreasing the absorption of talinolol [35].","label":[[0,9,"Herb name"],[11,18,"Amount"],[18,22,"Frequency"],[23,33,"Duration"],[39,55,"Extraction process"],[57,63,"Amount"],[67,77,"Extraction process"],[91,106,"Target"],[145,154,"Drug"]],"Comments":[]}
{"id":4035,"text":"Green tea and its marker component, epigallocatechin gallate, can also suppress the absorption of naldolol and rosuvastatin via the inhibition of intestinal OATP [35].","label":[[0,9,"Herb name"],[36,60,"Herb name"],[98,106,"Drug"],[111,123,"Drug"],[146,161,"Target"]],"Comments":[]}
{"id":4036,"text":"Given the importance of OATP (in human) and Oatp (in rat) in the pharmacokinetics and biliary excretion of valsartan [29,30], we monitored Oatp-mediated in vivo herb–drug interactions using valsartan as a substrate for Oatps in rats.","label":[[24,28,"Target"],[44,48,"Target"],[107,116,"Drug"],[139,143,"Target"],[190,199,"Drug"],[219,224,"Target"]],"Comments":[]}
{"id":4037,"text":"The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb–drug interactions involving valsartan (Figure 5 and Figure 8).","label":[[57,60,"Herb name"],[78,80,"Herb name"],[143,152,"Drug"]],"Comments":[]}
{"id":4038,"text":"Among PPD-type ginsenosides that inhibited in vitro OATP function, ginsenosides Rb1, Rb2, and Rc demonstrated high affinity for OATP1B3 inhibition (1.9–5.1 μM for OATP1B3; Figure 7).","label":[[6,27,"Herb name"],[43,51,"Study"],[52,56,"Target"],[67,79,"Herb name"],[80,83,"Herb name"],[85,88,"Herb name"],[94,96,"Herb name"],[128,135,"Target"],[148,158,"Amount"],[163,170,"Target"]],"Comments":[]}
{"id":4039,"text":"However, the maximum plasma concentrations (C Co-administration of valsartan and Rc (3 mg\/kg\/day, iv for 5 days) resulted in the lack of herb–drug interaction between Rc and valsartan.","label":[[13,42,"Parameter"],[67,76,"Drug"],[81,83,"Herb name"],[85,92,"Amount"],[92,96,"Frequency"],[101,111,"Duration"],[167,169,"Herb name"],[174,183,"Drug"]],"Comments":[]}
{"id":4040,"text":"The plasma concentration was ranged from 7.8 μM to 34.1 μM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1–0.2% in rat plasma, 0.4–0.5% in rat liver; Figure 9B).","label":[[83,121,"Herb name"],[123,126,"Herb name"],[128,131,"Herb name"],[137,139,"Herb name"]],"Comments":[]}
{"id":4041,"text":"Moreover, the tri-glycosylated ginsenosides are hydrophilic and bulky and, thus, they are difficult to be readily distributed in the liver tissue.","label":[[14,43,"Herb name"]],"Comments":[]}
{"id":4042,"text":"Taken together, high protein binding and limited liver distribution of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) might contribute to the lack of in vivo pharmacokinetic herb–drug interactions involving valsartan in rats although their plasma concentration was maximized following repeated intravenous injection of single ginsenoside.","label":[[71,109,"Herb name"],[111,114,"Herb name"],[116,119,"Herb name"],[125,127,"Herb name"],[218,227,"Drug"],[337,348,"Herb name"]],"Comments":[]}
{"id":4043,"text":"Jiang et al.","label":[],"Comments":[]}
{"id":4044,"text":"[23] reported that the unbound fraction of PPD-type ginsenosides was very low (0.4–0.9% in Rb1, Rc, and Rd) in the human plasma.","label":[[43,64,"Herb name"],[91,94,"Herb name"],[96,98,"Herb name"],[104,106,"Herb name"]],"Comments":[]}
{"id":4045,"text":"Based on the similarity in the structure and protein binding features between rats and human and inhibitory effect on OATP transporters of Rb1, Rb2, and Rc, limited herb–drug interaction between valsartan and ginsenoside Rb1, Rb2, and Rc would be expected in human.","label":[[118,122,"Target"],[139,142,"Herb name"],[144,147,"Herb name"],[153,155,"Herb name"],[195,204,"Drug"],[209,220,"Herb name"],[221,224,"Herb name"],[226,229,"Herb name"],[235,237,"Herb name"]],"Comments":[]}
{"id":4046,"text":"In case of co-administration of valsartan and rifampin, a significant drug interaction between valsartan and rifampin was found (Figure 5A) because unbound concentration of rifampin (4.7–22.9 μM) would exceed the IC Clinical herb–drug interactions between ginseng or ginsenosides and OATP1B1 or OATP1B3 have not been fully investigated.","label":[[32,41,"Drug"],[46,54,"Drug"],[95,104,"Drug"],[109,117,"Drug"],[173,181,"Drug"],[183,194,"Amount"],[213,215,"Parameter"],[256,263,"Herb name"],[267,279,"Herb name"],[284,291,"Target"],[295,302,"Target"]],"Comments":[]}
{"id":4047,"text":"Nevertheless, in a previous study, single or repeated administration of red ginseng solution (>60% dried ginseng, three pouches\/day once or for 2 weeks; equivalent to 85 mg total ginsenosides) did not have clinically significant inhibitory effects on the pharmacokinetics of pitavastatin, a selective substrate for OATP1B1 [14].","label":[[72,83,"Herb name"],[84,92,"Extraction process"],[99,104,"Extraction process"],[105,112,"Herb name"],[114,127,"Amount"],[127,131,"Frequency"],[140,151,"Duration"],[167,172,"Amount"],[179,191,"Herb name"],[275,287,"Drug"],[315,322,"Target"]],"Comments":[]}
{"id":4048,"text":"Furthermore, the clinically relevant pharmacokinetic ginseng or ginsenosides-valsartan interaction may not be caused based on the maximum concentrations of ginsenosides Rb1, Rb2, and Rc (6.2–12.7 nM) in human blood after repeated administration of red ginseng extract at high daily dose (3 g\/day) [14,41].","label":[[53,60,"Herb name"],[64,76,"Herb name"],[77,86,"Drug"],[130,152,"Parameter"],[156,168,"Herb name"],[169,172,"Herb name"],[174,177,"Herb name"],[183,185,"Herb name"],[187,198,"Amount"],[249,267,"Herb name"],[276,286,"Frequency"],[288,291,"Amount"]],"Comments":[]}
{"id":4049,"text":"In addition, 82-year-old male patient who took atorvastatin (80 mg), atenolol (50 mg), and aspirin (100 mg) reported drug-induced liver injury after concomitant ginseng intake.","label":[[13,24,"Age"],[25,29,"Sex"],[47,59,"Drug"],[61,66,"Amount"],[69,77,"Drug"],[79,84,"Amount"],[91,98,"Drug"],[100,106,"Amount"],[117,142,"Pathology"],[161,168,"Herb name"]],"Comments":[]}
{"id":4050,"text":"The patient’s symptoms regarding liver injury were resolved within 2 months after the cessation of both atorvastatin and the ginseng product [42].","label":[[33,45,"Pathology"],[60,75,"Duration"],[104,116,"Drug"],[125,132,"Herb name"]],"Comments":[]}
{"id":4051,"text":"After that, the case of liver injury might be deduced by the impaired elimination of atorvastatin through the inhibition of CYP3A4 and\/or OATP1B1 activity by ginseng product [42].","label":[[24,36,"Pathology"],[85,97,"Drug"],[124,130,"Target"],[138,145,"Target"],[158,165,"Herb name"]],"Comments":[]}
{"id":4052,"text":"However, based on the present results, the atorvastatin-induced liver injury in this patient may not be attributed to ginseng-atorvastatin interactions involving OATP1B1.","label":[[43,55,"Drug"],[43,76,"Pathology"],[118,125,"Herb name"],[126,138,"Drug"],[162,169,"Target"]],"Comments":[]}
{"id":4053,"text":"The benefits of ginseng and ginsenosides have been reported in cardiovascular diseases [2].","label":[[16,23,"Herb name"],[28,40,"Herb name"],[63,86,"Pathology"]],"Comments":[]}
{"id":4054,"text":"Ginseng is also widely used for individuals with cardiovascular risk factors such as hypertension and hypercholesterolemia [2].","label":[[0,7,"Herb name"],[85,97,"Pathology"],[102,122,"Pathology"]],"Comments":[]}
{"id":4055,"text":"The ginsenoside Rc has been found to have analgesic, anti-allergic, anti-tumor, and sedative effects [43].","label":[[4,18,"Herb name"]],"Comments":[]}
{"id":4056,"text":"The ginsenoside Rc may also be a strong anti-diabetic agent because it can markedly enhance glucose uptake [44].","label":[[4,18,"Herb name"]],"Comments":[]}
{"id":4057,"text":"Therefore, in conclusion, the findings showing the lack of herb–drug interactions between RGE or ginsenoside Rc and valsartan would provide useful information for patients taking anti-hypertensive, anti-diabetics, anti-tumor drugs such as valsartan and repaglinide that are substrate for OATPs transporters.","label":[[90,93,"Herb name"],[97,111,"Herb name"],[116,125,"Drug"],[179,196,"Drug"],[198,212,"Drug"],[214,230,"Drug"],[239,248,"Drug"],[253,264,"Drug"],[288,293,"Target"]],"Comments":[]}
{"id":4058,"text":"RGE was purchased from the Punggi Ginseng Cooperative Association (Youngjoo, Kyungpook, Korea).","label":[[0,3,"Herb name"]],"Comments":[]}
{"id":4059,"text":"The ginsenosides Rb1, Rb2, Rc, Rd, Rg1, Rg3, Rh1, Rh2, compound K, Re, PPD, and PPT were purchased from the Ambo Institute (Daejeon, Korea).","label":[[4,16,"Herb name"],[17,20,"Herb name"],[22,25,"Herb name"],[27,29,"Herb name"],[31,33,"Herb name"],[35,38,"Herb name"],[40,43,"Herb name"],[45,48,"Herb name"],[50,53,"Herb name"],[55,65,"Herb name"],[67,69,"Herb name"],[71,74,"Herb name"],[80,83,"Herb name"]],"Comments":[]}
{"id":4060,"text":"Berberine, caffeine, valsartan, probenecid, rifampin, TEA, sodium dodecyl sulfate (SDS), and Hank’s balanced salt solution (HBSS) were obtained from Sigma-Aldrich (St. Louis, MO, USA).","label":[[0,9,"Herb name"],[11,19,"Herb name"],[21,30,"Drug"],[32,42,"Drug"],[44,52,"Drug"],[54,57,"Herb name"]],"Comments":[]}
{"id":4061,"text":"Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), non-essential amino acids, and poly-D-lysine-coated 96-well plates were purchased from Corning Life Sciences (Woburn, MA, USA).","label":[],"Comments":[]}
{"id":4062,"text":"[ HEK293 cells overexpressing the OCT1, OCT2, OAT1, OAT3, OATP1B1, and OATP1B3 transporters (HEK293-OCT1, -OCT2, -OAT1, -OAT3, -OATP1B1, and -OATP1B3, respectively) and HEK293-mock cells (Corning Life Sciences; Woburn, MA, USA) were used and characterized as previously described [26,45,46].","label":[[34,38,"Target"],[40,44,"Target"],[46,50,"Target"],[52,56,"Target"],[58,65,"Target"],[71,78,"Target"],[100,104,"Target"],[107,111,"Target"],[114,118,"Target"],[121,125,"Target"],[128,135,"Target"],[142,149,"Target"]],"Comments":[]}
{"id":4063,"text":"HEK293 cells overexpressing drug transporters and HEK293-mock cells were seeded in poly-D-lysine-coated 96-well plates at a density of 10 To examine the effects of ginsenosides and typical inhibitors on transporter activity, aliquots (100 μL) of HBSS containing the probe substrate and ginsenosides or typical inhibitors were added to the cells after aspirating pre-incubated HBSS.","label":[[164,176,"Herb name"],[286,298,"Herb name"]],"Comments":[]}
{"id":4064,"text":"The concentrations and probe substrates were as follows: 0.1 μM [ The uptake of valsartan 5 (μM)was measured for 5 min immediately after adding aliquots (100 μL) of HBSS containing 5 μM valsartan in the presence or absence of rifampin (1–100 μM) or tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc; 0.1–100 μM) to the HEK293-mock cells and HEK293-OATP1B1 and –OAPT1B3 cells after aspirating pre-incubated HBSS.","label":[[80,89,"Drug"],[186,195,"Drug"],[226,234,"Drug"],[249,287,"Herb name"],[289,292,"Herb name"],[294,297,"Herb name"],[303,305,"Herb name"],[355,362,"Target"],[368,375,"Target"]],"Comments":[]}
{"id":4065,"text":"After 5 min incubation, the cells were washed three times with 100 μL of ice-cold HBSS, followed by lysing with 300 μL of 80% ice-cold methanol containing berberine 0.05 ng\/mL and 0.1% formic acid for 15 min.","label":[[155,164,"Herb name"]],"Comments":[]}
{"id":4066,"text":"After the centrifugation of cell lysate samples (16,000× g, 5 min, 4 °C), aliquots (4 μL) of cell lysate samples were injected into LC-MS\/MS system for the analysis of valsartan.","label":[[168,177,"Drug"]],"Comments":[]}
{"id":4067,"text":"Transporter mediated uptake of probe substrates or valsartan was calculated by subtracting the uptake rate of probe substrates or valsartan into HEK293-mock cells from that into HEK293 cells expressing respective transporters.","label":[[51,60,"Drug"],[130,139,"Drug"]],"Comments":[]}
{"id":4068,"text":"Male Sprague-Dawley rats (6–7-weeks old, 220–250 g) were purchased from Samtako Co. (Osan, Korea).","label":[[0,4,"Sex"],[26,39,"Age"]],"Comments":[]}
{"id":4069,"text":"The animals were acclimatized for 1 week in an animal facility at Kyungpook National University.","label":[],"Comments":[]}
{"id":4070,"text":"Food and water were provided ad libitum.","label":[],"Comments":[]}
{"id":4071,"text":"All animal procedures were approved by the Animal Care and Use Committee of Kyungpook National University (Approval No.","label":[],"Comments":[]}
{"id":4072,"text":"KNU 2017-21 and KNU 2019-83).","label":[],"Comments":[]}
{"id":4073,"text":"To calculate and compare the pharmacokinetic parameters of valsartan and ginsenosides, we performed repeated blood sampling through the retro-orbital puncture under isoflurane anesthesia.","label":[[59,69,"Drug"],[73,85,"Herb name"]],"Comments":[]}
{"id":4074,"text":"During the experimental procedure, rats did not suffer from any significant injury or infection.","label":[[76,82,"Pathology"],[86,95,"Pathology"]],"Comments":[]}
{"id":4075,"text":"The rats were randomly divided into the control and rifampin groups.","label":[[52,60,"Drug"]],"Comments":[]}
{"id":4076,"text":"The rifampin group was orally administered with rifampin solution (20 mg\/2 mL\/kg, dissolved in DMSO: saline = 2:8, v\/v) and the control group received only the vehicle via oral gavage.","label":[[4,12,"Drug"],[48,56,"Drug"],[67,80,"Amount"]],"Comments":[]}
{"id":4077,"text":"Valsartan was injected intravenously to both groups via the tail vein at 1 mg\/mL\/kg (dissolved in DMSO: saline = 2:8, v\/v).","label":[[0,9,"Drug"],[73,83,"Amount"]],"Comments":[]}
{"id":4078,"text":"Blood samples were collected via the retro-orbital vein at 0.25, 0.5, 1, 2, 4, 8, and 24 h following valsartan dosing.","label":[[101,110,"Drug"]],"Comments":[]}
{"id":4079,"text":"After the centrifugation of blood samples (16,000× g, 10 min, 4 °C), aliquots (50 μL each) of plasma samples were stored at –80 °C until the analysis of valsartan.","label":[[153,162,"Drug"]],"Comments":[]}
{"id":4080,"text":"The rats were randomly divided into the control and RGE groups.","label":[[52,56,"Herb name"]],"Comments":[]}
{"id":4081,"text":"The RGE group received a RGE suspension (1.5 g\/mL\/kg\/day, in distilled water) for 7 days via oral gavage.","label":[[4,7,"Herb name"],[25,28,"Herb name"],[41,52,"Amount"],[52,56,"Frequency"],[78,88,"Duration"]],"Comments":[]}
{"id":4082,"text":"The control group received distilled water for 7 days via oral gavage.","label":[[43,53,"Duration"]],"Comments":[]}
{"id":4083,"text":"After 1 h following the last RGE treatment, valsartan was injected intravenously to both groups via the tail vein at 1 mg\/mL\/kg (dissolved in DMSO: saline = 2:8, v\/v).","label":[[29,32,"Herb name"],[44,53,"Drug"],[117,127,"Amount"]],"Comments":[]}
{"id":4084,"text":"Blood samples were collected via the retro-orbital vein at 0.25, 0.5, 1, 2, 4, 8, 24, 30, and 48 h after valsartan dosing.","label":[[105,114,"Drug"]],"Comments":[]}
{"id":4085,"text":"After centrifugation of the blood samples at 16,000× g for 10 min, aliquots (50 μL each) of plasma samples were stored at −80 °C until the analysis of ginsenosides and valsartan.","label":[[151,163,"Herb name"],[168,177,"Drug"]],"Comments":[]}
{"id":4086,"text":"The rats were randomly divided into the control and Rc groups.","label":[[52,54,"Herb name"]],"Comments":[]}
{"id":4087,"text":"The Rc group was injected with Rc solution (3 mg\/mL\/kg, dissolved in saline) intravenously via the tail vein for 5 consecutive days.","label":[[4,6,"Herb name"],[31,33,"Herb name"],[44,54,"Amount"],[109,131,"Duration"]],"Comments":[]}
{"id":4088,"text":"The control group received saline (1 mL\/kg) for 5 consecutive days via the tail vein.","label":[[35,42,"Amount"],[44,66,"Duration"]],"Comments":[]}
{"id":4089,"text":"After 1 h following the last Rc treatment, valsartan was injected intravenously via the femoral vein at 1 mg\/kg.","label":[[29,31,"Herb name"],[43,52,"Drug"],[104,111,"Amount"]],"Comments":[]}
{"id":4090,"text":"Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.","label":[[110,119,"Drug"]],"Comments":[]}
{"id":4091,"text":"After centrifugation of the blood samples (16,000× g, 10 min, 4 °C), aliquots (50 μL each) of plasma samples were stored at −80 °C until the analysis of the ginsenoside Rc and valsartan.","label":[[157,171,"Herb name"],[176,185,"Drug"]],"Comments":[]}
{"id":4092,"text":"The rats were injected with Rc solution (3 mg\/mL\/kg, dissolved in saline) via the tail vein.","label":[[28,30,"Herb name"],[41,51,"Amount"]],"Comments":[]}
{"id":4093,"text":"Blood samples were collected from the abdominal artery, and the liver tissue was immediately excised, gently washed with ice-cold saline, and weighed after the rats were euthanized at 2, 12, and 48 h after intravenous injection of Rc.","label":[[231,233,"Herb name"]],"Comments":[]}
{"id":4094,"text":"The blood samples were centrifuged (16,000× g, 10 min, 4 °C) and the liver tissue samples were homogenized with four volumes of saline.","label":[],"Comments":[]}
{"id":4095,"text":"Aliquots (50 μL each) of plasma and liver homogenates were stored at −80 °C until the analysis of the ginsenoside Rc.","label":[[102,116,"Herb name"]],"Comments":[]}
{"id":4096,"text":"The protein binding of Rb1, Rb2, and Rc (1 μM) in rat plasma and liver homogenate was determined using a rapid equilibrium dialysis kit (ThermoFisher Scientific Korea, Seoul, Korea) according to the manufacturer’s instructions.","label":[[23,26,"Herb name"],[28,31,"Herb name"],[37,39,"Herb name"],[41,45,"Amount"]],"Comments":[]}
{"id":4097,"text":"Briefly, 100 μL of rat plasma and 10% liver homogenate samples containing Rb1, Rb2, or Rc (1 μM) were added to the sample chamber of a semipermeable membrane (molecular weight cut-off 8000 Da) and 300 μL of HBSS was added to the outer buffer chamber.","label":[[74,77,"Herb name"],[79,82,"Herb name"],[87,89,"Herb name"],[91,95,"Amount"]],"Comments":[]}
{"id":4098,"text":"Four hours after incubation at 37 °C on a shaking incubator at 300 rpm, aliquots (50 μL) were collected from both the sample and buffer chambers and treated with equal volumes of fresh HBSS and plasma, respectively, to match the sample matrices.","label":[],"Comments":[]}
{"id":4099,"text":"The matrix-matched samples (100 μL) were mixed with 300 μL of 80% ice-cold methanol containing berberine 0.05 ng\/mL and 0.1% formic acid for 15 min.","label":[[95,104,"Herb name"]],"Comments":[]}
{"id":4100,"text":"After centrifugation (16,100× g, 5 min, 4  Plasma protein binding was calculated using the following equation [47].","label":[],"Comments":[]}
{"id":4101,"text":"Tissue protein binding was calculated using the following equations, and a dilution factor (D as a value of 10) was used since we used 10% liver homognenates [47,48].","label":[],"Comments":[]}
{"id":4102,"text":"The concentration of valsartan was analyzed using a modified Liquid chromatography–mass spectrometry (LC-MS\/MS) method as previously reported by Yamashiro et al.","label":[[21,30,"Drug"]],"Comments":[]}
{"id":4103,"text":"[29] using an Agilent 6470 Triple Quad LC–MS\/MS system (Agilent, Wilmington, DE, USA).","label":[],"Comments":[]}
{"id":4104,"text":"Briefly, aliquots (50 μL) of plasma samples were mixed with 350 μL of an internal standard (IS) solution (berberine 0.05 ng\/mL in methanol) and the mixtures were vortexed for 15 min.","label":[[106,115,"Herb name"]],"Comments":[]}
{"id":4105,"text":"After centrifugation (16,100× g, 5 min, 4 °C), 100 μL of the supernatant was transferred to a clean tube, evaporated and an aliquot (4 μL) from the sample was injected into LC-MS\/MS system.","label":[],"Comments":[]}
{"id":4106,"text":"The samples were eluted through a Synergy Polar RP column (2.0 mm × 150 mm, 4 µm particle size) (Phenomenex, Torrance, CA, USA) using a mobile phase consisting of methanol and water (75:25, v\/v) with 0.1% formic acid at a flow rate of 0.2 mL\/min.","label":[],"Comments":[]}
{"id":4107,"text":"Valsartan and berberine (IS) were detected at a retention time (T The concentration of compound K was analyzed using a modified LC-MS\/MS method of Jin et al.","label":[[0,9,"Drug"],[14,23,"Herb name"],[87,97,"Herb name"]],"Comments":[]}
{"id":4108,"text":"[31] using an Agilent 6470 Triple Quad LC–MS\/MS system (Agilent, Wilmington, DE, USA).","label":[],"Comments":[]}
{"id":4109,"text":"For the detection of Rb1, Rb2, Rc, Rd, Re, Rg1, Rh2, and Rg3, aliquots (50 μL) of plasma and liver homogenates were mixed with 350 μL of IS solution (0.05 ng\/mL berberine in methanol) and vortexed for 15 min.","label":[[21,24,"Herb name"],[26,29,"Herb name"],[31,33,"Herb name"],[35,37,"Herb name"],[39,41,"Herb name"],[43,46,"Herb name"],[48,51,"Herb name"],[57,60,"Herb name"],[161,170,"Herb name"]],"Comments":[]}
{"id":4110,"text":"After centrifugation (16,100× g for 5 min, 4 °C), 200 μL of the supernatant was transferred to a clean tube and evaporated.","label":[],"Comments":[]}
{"id":4111,"text":"The residue was reconstituted with 100 μL of 70% methanol consisting of 0.1% formic acid.","label":[],"Comments":[]}
{"id":4112,"text":"An aliquot (20 μL) from the sample was injected into the LC-MS\/MS system.","label":[],"Comments":[]}
{"id":4113,"text":"The samples were eluted through a Synergy Polar RP column (2.0 mm × 150 mm, 4 µm particle size) (Phenomenex, Torrance, CA, USA) with a gradient mobile phase consisting of 0.1% formic acid in water (phase A) and 0.1% formic acid in methanol (phase B) as follows: 69% of phase B for 0–2.0 min, 69–85% of phase B for 2.0–4.0 min, and 85–69% of phase B for 6.0–6.5 min at a flow rate of 0.27 mL\/min.","label":[],"Comments":[]}
{"id":4114,"text":"The ginsenosides Rb1, Rb2, Rc, Rd, Re, Rg1, Rh2, Rg3, and berberine (IS) were detected at m\/z 1131.6 → 365.1 (for Rb1, T For the detection of Rh1, compound K, PPD, and PPT, aliquots (50 μL) of plasma and liver homogenates were mixed with 50 μL of IS solution (25 ng\/mL caffeine in water) and 600 μL of methyl tertiary-butyl ether (MTBE), vortexed for 15 min, and centrifuged at 16,100× g for 5 min.","label":[[4,16,"Herb name"],[17,20,"Herb name"],[22,25,"Herb name"],[27,29,"Herb name"],[31,33,"Herb name"],[35,37,"Herb name"],[39,42,"Herb name"],[44,47,"Herb name"],[49,52,"Herb name"],[58,67,"Herb name"],[114,117,"Herb name"],[142,145,"Herb name"],[147,157,"Herb name"],[159,162,"Herb name"],[168,171,"Herb name"],[269,277,"Herb name"]],"Comments":[]}
{"id":4115,"text":"After freezing the aqueous layer at −80 °C for 2 h, the upper organic layer was transferred to a clean tube and evaporated to dryness.","label":[],"Comments":[]}
{"id":4116,"text":"The residue was reconstituted with 150 μL of 85% methanol.","label":[],"Comments":[]}
{"id":4117,"text":"An aliquot (20 μL) from the sample was injected into the LC-MS\/MS system.","label":[],"Comments":[]}
{"id":4118,"text":"The samples were eluted through an Omega Polar C18 column (2.1 mm × 100 mm, 3 µm particle size) (Phenomenex, Torrance, CA, USA) using a mobile phase consisting of 0.1% formic acid in water: 0.1% formic acid in methanol (15:85, v\/v) at a flow rate of 0.2 mL\/min.","label":[],"Comments":[]}
{"id":4119,"text":"The ginsenosides Rh1, Rh2, compound K, PPD, PPT, and caffeine (IS) were detected at m\/z 603.4 → 423.4 (for Rh1, T In the inhibition studies, the uptake rate of substrate by HEK293 cells overexpressing the respective transporters was used as the control (100%) and the uptake rate of substrates in the presence of typical inhibitors or ginsenosides expressed as a percentage of the control.","label":[[4,16,"Herb name"],[17,20,"Herb name"],[22,25,"Herb name"],[27,37,"Herb name"],[39,42,"Herb name"],[44,47,"Herb name"],[53,61,"Herb name"],[107,110,"Herb name"],[335,347,"Herb name"]],"Comments":[]}
{"id":4120,"text":"The inhibition data were fitted to an inhibitory effect model [26] using Sigma plot (version 10.0; Systat Software Inc., San Jose, CA, USA).","label":[],"Comments":[]}
{"id":4121,"text":"IC Pharmacokinetic parameters were calculated from plasma concentration-time profile using non-compartment analysis of WinNonlin (version 5.1; Pharsights, Cary, NC, USA).","label":[[0,2,"Parameter"]],"Comments":[]}
{"id":4122,"text":"The statistical significance was assessed by t-test using Statistical Package for the Social Sciences (version 24.0; SPSS Inc., Chicago, IL, USA).","label":[],"Comments":[]}
{"id":4123,"text":"Sample Availability: Not available.","label":[],"Comments":[]}
{"id":4124,"text":"Conceptualization: I.-S.S.; methodology, J.-H.J, S.J., and M.-K.C.","label":[],"Comments":[]}
{"id":4125,"text":"; validation, J.-H.J, S.J., and M.-K.C.","label":[],"Comments":[]}
{"id":4126,"text":"; formal analysis, W.L.","label":[],"Comments":[]}
{"id":4127,"text":"; investigation, J.-H.J, S.L., W.L., S.J., M.K., C.H.S., and I.-S.S.; writing—original draft preparation, J.-H.J.","label":[],"Comments":[]}
{"id":4128,"text":"and I.-S.S.; writing—review and editing, M.-K.C.","label":[],"Comments":[]}
{"id":4129,"text":"and I.-S.S.; supervision, I.-S.S.; project administration, I.-S.S.; funding acquisition, I.-S.S. All authors have read and agreed to the published version of the manuscript.","label":[],"Comments":[]}
{"id":4130,"text":"This research was supported by Kyungpook National University Development Project Research Fund, 2018.","label":[],"Comments":[]}
{"id":4131,"text":"The authors declare no conflict of interest.","label":[],"Comments":[]}
{"id":4132,"text":"Inhibitory effect of typical inhibitors on the (A) OCT1, (B) OCT2, (C) OAT1, (D) OAT3, (E) OATP1B1, and (F) OATP1B3-mediated uptake.","label":[[51,55,"Target"],[61,65,"Target"],[71,75,"Target"],[81,85,"Target"],[91,98,"Target"],[108,115,"Target"]],"Comments":[]}
{"id":4133,"text":"Transporter mediated uptake of probe substrate were calculated by subtracting the uptake in HEK293-mock cells from the uptake in HEK293 cells overexpressing respective transporters.","label":[],"Comments":[]}
{"id":4134,"text":"The concentrations and probe substrates were as follows: 0.1 μM [ Inhibitory effect of Rb1, Rb2, Rc, Rd, compound K, Rg3, Rh2, PPD, PPT, Re, Rg1, and Rh1 on the OATP1B1-mediated transport of [ Inhibitory effect of Rb1, Rb2, Rc, Rd, compound K, Rg3, Rh2, PPD, PPT, Re, Rg1, and Rh1 on the OATP1B3-mediated uptake of [ (A) Uptake of valsartan (5 μM) by HEK293-mock cells and HEK293 cells expressing OATP1B1 and OATP1B3.","label":[[57,63,"Amount"],[87,90,"Herb name"],[92,95,"Herb name"],[97,99,"Herb name"],[101,103,"Herb name"],[105,115,"Herb name"],[117,120,"Herb name"],[122,125,"Herb name"],[127,130,"Herb name"],[132,135,"Herb name"],[137,139,"Herb name"],[141,144,"Herb name"],[150,153,"Herb name"],[161,168,"Target"],[214,217,"Herb name"],[219,222,"Herb name"],[224,226,"Herb name"],[228,230,"Herb name"],[232,242,"Herb name"],[244,247,"Herb name"],[249,252,"Herb name"],[254,257,"Herb name"],[259,262,"Herb name"],[264,266,"Herb name"],[268,271,"Herb name"],[277,280,"Herb name"],[288,295,"Herb name"],[331,340,"Drug"],[342,346,"Amount"],[397,404,"Target"],[409,416,"Target"]],"Comments":[]}
{"id":4135,"text":"Inhibitory effect of rifampin on the (B) OATP1B1- and (C) OATP1B3-mediated uptake of valsartan.","label":[[21,29,"Drug"],[41,48,"Target"],[58,65,"Target"],[85,94,"Drug"]],"Comments":[]}
{"id":4136,"text":"Data points represent the mean ± SD from triplicate measurements.","label":[],"Comments":[]}
{"id":4137,"text":"*p < 0.05 compared with HEK293-mock cells.","label":[],"Comments":[]}
{"id":4138,"text":"(A) Plasma concentration-time profile of valsartan in the control and rifampin (20 mg\/kg) groups following intravenous injection of valsartan at a dose of 1 mg\/kg in rats.","label":[[41,50,"Drug"],[70,78,"Drug"],[80,88,"Amount"],[132,141,"Drug"],[155,162,"Amount"]],"Comments":[]}
{"id":4139,"text":"(B) Plasma concentration-time profile of valsartan in the control and red ginseng extract (RGE, 1.5 g\/kg\/day for 7 days) groups following intravenous injection of valsartan at a dose of 1 mg\/kg in rats.","label":[[41,50,"Drug"],[70,94,"Herb name"],[96,104,"Amount"],[104,108,"Frequency"],[109,119,"Duration"],[163,172,"Drug"],[186,193,"Amount"]],"Comments":[]}
{"id":4140,"text":"Data points represent the mean ± SD of four different rats per group.","label":[],"Comments":[]}
{"id":4141,"text":"Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).","label":[[42,54,"Herb name"],[59,62,"Herb name"],[68,71,"Herb name"],[77,79,"Herb name"],[85,87,"Herb name"],[93,96,"Herb name"],[106,109,"Herb name"],[134,140,"Duration"],[168,193,"Herb name"]],"Comments":[]}
{"id":4142,"text":"Data represent the mean ± SD of four rats.","label":[],"Comments":[]}
{"id":4143,"text":"Inhibitory effect of Rb1 (A,D), Rb2 (B,E), and Rc (C,F) on the OATP1B1- and OATP1B3-mediated uptake of valsartan.","label":[[21,24,"Herb name"],[32,35,"Herb name"],[47,49,"Herb name"],[63,70,"Target"],[76,83,"Target"],[103,112,"Drug"]],"Comments":[]}
{"id":4144,"text":"OATP1B1- and OATP1B3-mediated valsartan uptake was calculated by subtracting valsartan uptake (5 μM) by HEK293-mock cells from valsartan uptake (5 μM) by HEK293-OATP1B1 and -OATP1B3 cells, respectively.","label":[[0,7,"Target"],[13,20,"Target"],[30,39,"Drug"],[77,86,"Drug"],[95,99,"Amount"],[127,136,"Drug"],[145,149,"Amount"],[161,168,"Drug"],[174,181,"Target"]],"Comments":[]}
{"id":4145,"text":"Data points represent the mean ± SD from triplicate measurements.","label":[],"Comments":[]}
{"id":4146,"text":"(A) Plasma concentration-time profile of valsartan in the control and Rc groups following intravenous injection of valsartan at a dose of 1 mg\/kg.","label":[[41,50,"Drug"],[70,72,"Herb name"],[115,124,"Drug"],[138,145,"Amount"]],"Comments":[]}
{"id":4147,"text":"Rc was injected intravenously for 5 days at a dose of 3 mg\/kg\/day.","label":[[0,2,"Herb name"],[30,40,"Duration"],[54,61,"Amount"],[61,65,"Frequency"]],"Comments":[]}
{"id":4148,"text":"(B) Plasma concentration-time profile of Rc in the Rc group.","label":[[41,43,"Herb name"],[51,53,"Herb name"]],"Comments":[]}
{"id":4149,"text":"Data points represent the mean ± SD of three different rats per group.","label":[],"Comments":[]}
{"id":4150,"text":"(A) Plasma (●) and liver (○) concentrations of Rc following intravenous injection of Rc at a dose of 3 mg\/kg.","label":[[47,49,"Herb name"],[85,87,"Herb name"],[101,108,"Amount"]],"Comments":[]}
{"id":4151,"text":"(B) Protein binding of Rb1, Rb2, and Rc in the rat plasma and liver homogenates using a rapid equilibrium dialysis device.","label":[[23,26,"Herb name"],[28,31,"Herb name"],[37,39,"Herb name"]],"Comments":[]}
{"id":4152,"text":"Data were expressed as the mean ± SD of three different rats or triplicated measurements.","label":[],"Comments":[]}
{"id":4153,"text":"Inhibitory effect of ginsenosides on drug transporters.","label":[[21,33,"Herb name"]],"Comments":[]}
{"id":4154,"text":"NI: No significant inhibition; >100: weak inhibition but IC Pharmacokinetic parameters of valsartan following intravenous injection of valsartan at a dose of 1 mg\/kg in rats.","label":[[57,59,"Parameter"],[90,99,"Drug"],[135,144,"Drug"],[158,165,"Amount"]],"Comments":[]}
{"id":4155,"text":"Data represent mean ± SD of four rats per group.","label":[],"Comments":[]}
{"id":4156,"text":"* p < 0.05 compared with control group.","label":[],"Comments":[]}
{"id":4157,"text":"T Pharmacokinetic parameters of ginsenosides in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).","label":[[32,44,"Herb name"],[69,75,"Duration"],[103,128,"Herb name"]],"Comments":[]}
{"id":4158,"text":"Data represent mean ± SD of four rats per group.","label":[],"Comments":[]}
{"id":4159,"text":"AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg\/kg in rats.","label":[[0,26,"Parameter"],[99,108,"Drug"],[113,115,"Herb name"],[151,160,"Drug"],[174,181,"Amount"]],"Comments":[]}
{"id":4160,"text":"Data represent mean ± SD of three rats per group T","label":[],"Comments":[]}
